Nantahala Capital Takes New Stake in Talphera, May Seek Influence
Ticker: TLPH · Form: SC 13D · Filed: Jan 23, 2024 · CIK: 1427925
| Field | Detail |
|---|---|
| Company | Talphera, Inc. (TLPH) |
| Form Type | SC 13D |
| Filed Date | Jan 23, 2024 |
| Risk Level | medium |
| Pages | 10 |
| Reading Time | 12 min |
| Key Dollar Amounts | $0.001, $0.769, $5.00, $1,321,250, $1.11 |
| Sentiment | mixed |
Complexity: simple
Sentiment: mixed
Topics: insider-buy, activist-investing, institutional-ownership
TL;DR
**Nantahala Capital just revealed a big stake in Talphera, signaling potential activist moves.**
AI Summary
Nantahala Capital Management, LLC, a hedge fund, has disclosed a new significant stake in Talphera, Inc. (formerly AcelRx Pharmaceuticals Inc.) as of January 17, 2024. This filing indicates that Nantahala Capital Management, LLC, along with group members Daniel Mack and Wilmot B. Harkey, now holds a position that requires a Schedule 13D filing, suggesting they may seek to influence management or strategy. This matters to investors because a major institutional investor taking a large stake could signal confidence in the company's future or could lead to activist pressure for changes, potentially impacting the stock price.
Why It Matters
A significant stake by an activist investor like Nantahala Capital Management could lead to strategic changes at Talphera, potentially affecting its stock performance and future direction.
Risk Assessment
Risk Level: medium — The involvement of an activist investor can introduce both upside potential from strategic improvements and downside risk from disagreements or failed initiatives.
Analyst Insight
A smart investor would monitor Talphera, Inc. closely for any announcements regarding Nantahala Capital Management's intentions or any changes in company strategy, as this could signal potential upside or downside depending on the nature of their involvement.
Key Numbers
- 00444T209 — CUSIP Number (identifies Talphera, Inc.'s Common Stock)
- January 17, 2024 — Date of Event (date requiring the filing of this statement)
Key Players & Entities
- Nantahala Capital Management, LLC (company) — reporting person, hedge fund
- TALPHERA, INC. (company) — subject company, issuer
- Daniel Mack (person) — group member
- Wilmot B. Harkey (person) — group member
- Taki Vasilakis (person) — person authorized to receive notices for Nantahala Capital Management, LLC
- $0.001 (dollar_amount) — par value per share of Common Stock
Forward-Looking Statements
- Nantahala Capital Management, LLC will engage with Talphera's management to discuss strategic alternatives. (TALPHERA, INC.) — medium confidence, target: Q2 2024
- Talphera's stock price will experience increased volatility due to the activist stake. (TALPHERA, INC.) — high confidence, target: Q1 2024
FAQ
Who is the reporting person in this SC 13D filing?
The reporting person is Nantahala Capital Management, LLC, located at 130 Main St., 2nd Floor, New Canaan, CT 06840.
What is the name of the issuer whose securities are being reported?
The issuer is TALPHERA, INC., formerly known as ACELRX PHARMACEUTICALS INC., with its business address at 1850 Gateway Drive, Suite 175, San Mateo, CA 94404.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the Common Stock, par value $0.001 per share, of TALPHERA, INC. is 00444T209.
When was the event that required this Schedule 13D filing?
The date of the event which requires the filing of this statement was January 17, 2024.
Who are the identified group members associated with Nantahala Capital Management, LLC in this filing?
The identified group members are Daniel Mack and Wilmot B. Harkey.
Filing Stats: 2,918 words · 12 min read · ~10 pages · Grade level 12.3 · Accepted 2024-01-22 18:46:08
Key Financial Figures
- $0.001 — ame of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
- $0.769 — in Item 6. The Nantahala Investors paid $0.769 per Pre-Funded Warrant using cash on ha
- $5.00 — es of Common Stock on March 15, 2024 at $5.00 per share of Common Stock. The Call Opt
- $1,321,250 — mon Stock. The Nantahala Investors paid $1,321,250 to acquire the Call Options, using a po
- $1.11 — arrants, each exercisable initially for $1.11 per share of Common Stock (but see Item
- $4.75 million — mitted to make an initial investment of $4.75 million and a further $9.5 million equity inves
- $9.5 million — vestment of $4.75 million and a further $9.5 million equity investment in the Issuer (the &l
- $0.77 — ants held by the Nantahala Investors to $0.77 per share of Common Stock. The Reporti
- $0.7797 — Stock on December 7, 2023 at a price of $0.7797 per share, 2,519 shares of Common Stock
- $0.7571 — Stock on December 8, 2023 at a price of $0.7571 per share, and 2,102 shares of Common S
- $0.7254 — tock on December 11, 2023 at a price of $0.7254 per share. (d) The Nantahala Investors
Filing Documents
- tm243863d1_sc13d.htm (SC 13D) — 84KB
- tm243863d1_ex99-1.htm (EX-99.1) — 5KB
- 0001104659-24-005645.txt ( ) — 90KB
Signatures
Signatures After reasonable inquiry and to the best of their knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: January 22, 2024 NANTAHALA CAPITAL MANAGEMENT, LLC By: /s/ Taki Vasilakis Taki Vasilakis Chief Compliance Officer /s/ Wilmot B. Harkey Wilmot B. Harkey /s/ Daniel Mack Daniel Mack